Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Medical Affairs Reputations: Psoriasis (EU5)

Product Code:
596200580
Publication Date:
February 2016
Format:
PowerPoint
Price:
$6,685

Who has the best medical affairs team? In Europe, two brands dominate

Two medical affairs teams are fighting it out for top spot in the European psoriasis treatment market—and leaving the rest of the pack far behind. Ranked for overall quality of interactions these teams score at least 29% higher than their closest competitor.

How does your team rank?

Are you giving dermatologists the services that matter most to them? Are you available when and where they need you? What can you do to boost your team’s performance?

Get the report and find out.

Interested in the US market? Click here to see the US Edition.

Request Sample Pages

Answering Key Questions about Medical Affairs Teams for 9 Major Psoriasis Brands

AbbVie:
  • Humira (adalimumab): Which two important medical affairs services does Humira’s team need to improve?
Celgene:
  • Otezla (apremilast): Does Otezla’s team interact with dermatologists more or less often than Remicade’s team?
Janssen Cilag:
  • Stelara (ustekinumab): Does Stelara’s team earn higher satisfaction scores for responding promptly to medical inquiries or providing scientific and product information?
Merck Sharpe & Dohme:
  • Remicade (infliximab): Is Remicade’s team doing better than those of biosimilars Inflectra and Remsima?
Napp/Mundipharma:
  • Remsima (infliximab): Where do Remsima’s team’s satisfaction scores come closest to those of branded counterpart Remicade?
Novartis:
  • Cosentyx (secukinumab): Which brand’s team is gaining on Cosentyx in terms of overall quality score?
Pfizer:
  • Enbrel (etanercept): In which area does Enbrel’s team outperform one of the top 3 medical affairs teams?
  • Inflectra (infliximab): Which medical affairs service earns Inflectra’s team higher satisfaction scores than the other surveyed biosimilar, Remsima?

Top Takeaways

  • Biosimilars’ teams lagging: Their performance and satisfaction scores are consistently low, but they do rank ahead of one brand for overall satisfaction.
  • Room for improvement: Satisfaction is high in most, but not all of the areas important to dermatologists, and every team needs improvement in specific areas.
  • Clinical support role is key: The most important functions for medical affairs teams involve answering medical questions and providing clinical information, dermatologists say. 
  • Little interest in digital interactions: Less than half of dermatologists surveyed prefer email communications. Even fewer prefer other digital interactions. 
  • Clear suggestions for better services: Although overall satisfaction is high, dermatologists surveyed identified two key areas where teams can enhance their services.
  • Europe underperforms vs. US: US teams tend to score higher, and dermatologists are more satisfied with their performance in important areas. Get the US report for details.

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:

What do dermatologists need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team’s interactions with dermatologists?
  • How do dermatologists rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to dermatologists?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Dermatologists

We surveyed 150 dermatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with psoriasis in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the last 6 months.

We conducted the survey between January 4th and 15th, 2016.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved